Cocrystal Pharma, Inc. PP&E Disclosure
Property and equipment as of December 31, consists of the following (table in thousands):
| 2025 | 2024 | |||||||
| Lab equipment (excluding equipment under finance leases) | $ | 1,777 | $ | 1,765 | ||||
| Finance lease right-of-use lab equipment obtained in exchange for finance lease liabilities, net | 162 | 162 | ||||||
| Computer and office equipment | 155 | 155 | ||||||
| Total property and equipment | 2,094 | 2,082 | ||||||
| Less accumulated depreciation | (2,001 | ) | (1,929 | ) | ||||
| Property and equipment, net | $ | 93 | $ | 153 | ||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 31, 2026 | Showing above |
| 2024 | Mar 31, 2025 | |
| 2023 | Mar 28, 2024 | |
| 2022 | Mar 29, 2023 | |
| 2021 | Mar 23, 2022 | |
| 2020 | Mar 17, 2021 | |
| 2019 | Mar 27, 2020 | |
| 2018 | Apr 1, 2019 | |
| 2017 | Mar 21, 2018 | |
| 2016 | Mar 31, 2017 | |
| 2015 | Mar 15, 2016 | |
About PP&E Disclosures
The PP&E disclosure details a company's physical asset base — land, buildings, machinery, and equipment — along with the depreciation methods and useful life assumptions that determine how these costs flow through the income statement. Capitalization policy thresholds reveal management's judgment on the boundary between expense and asset, directly affecting both reported earnings and asset values.
Key signals: changes in estimated useful lives or depreciation methods can materially shift reported earnings without any operational change. Compare capital expenditures against depreciation expense — when capex consistently trails depreciation, the asset base may be aging and underinvested. Watch for large asset impairments or write-downs that signal overvalued carrying amounts. Asset retirement obligations reveal future environmental or decommissioning costs that are often underappreciated. Compare PP&E intensity (PP&E-to-revenue) against industry peers to assess capital efficiency and competitive positioning.